DNA Collection

Saliva sample collected in physician's office

Turn-around Time

10 to 15 days

Have a question?

References: References: 1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Genetic/familial high-risk assessment: breast and ovarian. Version 2.2015. National Comprehensive Cancer Network website. http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Published June 25, 2015. Accessed January 4, 2016. 2. Mavaddat N, Peock S, Frost D, et al; EMBRACE. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105(11):812-822. 3. Easton DF, Ford D, Bishop DT; Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet. 1995;56(1):265-271. 4. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117-1130. 5. Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2007;99(23):1811-1814. 6. Ford D, Easton DF, Stratton M, et al; Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998;62(3):676-689. 7. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329-1333.8. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review 1975-2012. National Cancer Institute Surveillance, Epidemiology, and End Results Program website. http://seer.cancer.gov/csr/1975_2012/. Posted April 2015. Updated November 18, 2015. Accessed January 4, 2016. 9. American College of Obstetricians and Gynecologists; ACOG Committee on Practice Bulletins–Gynecology; ACOG Committee on Genetics; Society of Gynecologic Oncologists. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol. 2009;113(4):957-966. 10. Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91(15):1310-1316. 11. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Ovarian cancer, including fallopian tube cancer and primary peritoneal cancer. Version 2.2015. National Comprehensive Cancer Network website. http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Published June 22, 2015. Accessed January 4, 2016.